Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II StudyJian Li, Lin Shen, Ye Zhou et al.|Clinical Cancer Research|2022Cited by 15
Clinical Benefit of Avapritinib in <i>KIT-</i> Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 StudiesMichael C. Heinrich, Lin Shen, Xinhua Zhang et al.|Clinical Cancer Research|2023Cited by 9